JP2001520998A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001520998A5 JP2001520998A5 JP2000517717A JP2000517717A JP2001520998A5 JP 2001520998 A5 JP2001520998 A5 JP 2001520998A5 JP 2000517717 A JP2000517717 A JP 2000517717A JP 2000517717 A JP2000517717 A JP 2000517717A JP 2001520998 A5 JP2001520998 A5 JP 2001520998A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- spla
- compound
- dioxoethyl
- indol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 3
- CXAFWBHDYGONMZ-UHFFFAOYSA-N 2-[2-methyl-3-oxamoyl-1-[(3-phenylphenyl)methyl]indol-4-yl]oxyacetic acid Chemical compound CC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)C=CC=C2N1CC(C=1)=CC=CC=1C1=CC=CC=C1 CXAFWBHDYGONMZ-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6364697P | 1997-10-27 | 1997-10-27 | |
| US60/063,646 | 1997-10-27 | ||
| PCT/US1998/022679 WO1999021559A1 (en) | 1997-10-27 | 1998-10-26 | MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001520998A JP2001520998A (ja) | 2001-11-06 |
| JP2001520998A5 true JP2001520998A5 (enExample) | 2006-01-05 |
Family
ID=22050578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000517717A Withdrawn JP2001520998A (ja) | 1997-10-27 | 1998-10-26 | インドールｓＰＬＡ２阻害剤のモルホリノ−Ｎ−エチルエステルプロドラッグ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6177426B1 (enExample) |
| EP (1) | EP1039911B1 (enExample) |
| JP (1) | JP2001520998A (enExample) |
| AT (1) | ATE296286T1 (enExample) |
| AU (1) | AU1200899A (enExample) |
| CA (1) | CA2308443A1 (enExample) |
| DE (1) | DE69830335T2 (enExample) |
| ES (1) | ES2241178T3 (enExample) |
| WO (1) | WO1999021559A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1200899A (en) | 1997-10-27 | 1999-05-17 | Eli Lilly And Company | Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors |
| US6274578B1 (en) | 1999-04-20 | 2001-08-14 | Eli Lilly And Company | sPLA2 inhibitor ester |
| US6140327A (en) * | 1999-05-12 | 2000-10-31 | Eli Lilly And Company | Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor |
| DE60032774D1 (de) * | 1999-07-19 | 2007-02-15 | Lilly Co Eli | Spla2 inhibitoren |
| US6706752B1 (en) | 1999-07-19 | 2004-03-16 | Eli Lilly And Company | sPLA2 inhibitors |
| US6831095B1 (en) | 1999-09-20 | 2004-12-14 | Eli Lilly And Company | Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors |
| DE60032254D1 (de) * | 1999-09-20 | 2007-01-18 | Lilly Co Eli | Hydroxyfunktionelle amid-1h-indolderivate aktiv als spla2 inhibitoren |
| DE19962300A1 (de) * | 1999-12-23 | 2001-06-28 | Asta Medica Ag | Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung |
| EP1303262A2 (en) * | 2000-07-14 | 2003-04-23 | Eli Lilly And Company | Use of a spla2 inhibitor for the treatment of sepsis |
| US20030124174A1 (en) * | 2001-10-25 | 2003-07-03 | Endo Pharmaceuticals, Inc | Method for treating non-neuropathic pain |
| AUPS282602A0 (en) | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
| EP4008327A1 (en) | 2009-04-29 | 2022-06-08 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| EP2887934A1 (en) * | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| US20140348915A9 (en) | 2012-08-22 | 2014-11-27 | Xenoport, Inc. | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| US9416096B2 (en) | 2013-09-06 | 2016-08-16 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) * | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CA3013407A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EA201992782A1 (ru) | 2017-05-22 | 2020-03-24 | Янссен Фармасьютикалз, Инк. | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге |
| EA039702B1 (ru) | 2017-05-22 | 2022-03-01 | Янссен Фармасьютикалз, Инк. | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE220394T1 (de) | 1994-04-01 | 2002-07-15 | Lilly Co Eli | 1h-indol-3-glyoxylamid spla2 inhibitoren |
| US5972988A (en) | 1997-03-26 | 1999-10-26 | Eli Lilly And Company | Method for treatment of chronic bronchitis using indole compounds |
| AU1200899A (en) | 1997-10-27 | 1999-05-17 | Eli Lilly And Company | Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors |
| AU1200799A (en) * | 1997-10-27 | 1999-05-17 | Eli Lilly And Company | Isopropyl ester prodrugs of indole spla2 inhibitors |
| CA2310249A1 (en) | 1997-11-14 | 1999-05-27 | August Masaru Watanabe | Treatment for alzheimer's disease |
-
1998
- 1998-10-26 AU AU12008/99A patent/AU1200899A/en not_active Abandoned
- 1998-10-26 DE DE69830335T patent/DE69830335T2/de not_active Expired - Fee Related
- 1998-10-26 JP JP2000517717A patent/JP2001520998A/ja not_active Withdrawn
- 1998-10-26 WO PCT/US1998/022679 patent/WO1999021559A1/en not_active Ceased
- 1998-10-26 ES ES98955125T patent/ES2241178T3/es not_active Expired - Lifetime
- 1998-10-26 US US09/509,755 patent/US6177426B1/en not_active Expired - Fee Related
- 1998-10-26 CA CA002308443A patent/CA2308443A1/en not_active Abandoned
- 1998-10-26 EP EP98955125A patent/EP1039911B1/en not_active Expired - Lifetime
- 1998-10-26 AT AT98955125T patent/ATE296286T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001520998A5 (enExample) | ||
| DK1950200T3 (da) | [[3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-(PHENYLMETHYL)-11H-INDOL-4-YL]OXY]EDDIKESYREMETHYLESTER SOM sPLA2-INHIBITOR | |
| JP2002518502A5 (enExample) | ||
| AU3392900A (en) | Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds | |
| CA2445145A1 (en) | Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes | |
| DE69924869D1 (de) | Medikament zur behandlung chronisch obstruktiver lungenerkrankung | |
| JP2004508410A5 (enExample) | ||
| WO1999047497A3 (en) | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment | |
| CA2382098A1 (en) | Sustained-release, oral pharmaceutical forms of administration | |
| CA2301017A1 (en) | Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds | |
| AU1200899A (en) | Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors | |
| CA2474904A1 (en) | Once-a-day oxycodone formulations | |
| JP2003503449A5 (enExample) | ||
| AU4327300A (en) | Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension | |
| JP2002509153A5 (enExample) | ||
| JP2002502836A5 (enExample) | ||
| JP2001520991A5 (enExample) | ||
| JP2005539045A5 (enExample) | ||
| WO2001019814A3 (en) | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment | |
| JP2002520286A5 (enExample) | ||
| JP2004537498A5 (enExample) | ||
| JP2002513761A5 (enExample) | ||
| JP2002506864A5 (enExample) | ||
| IL146197A0 (en) | Process for the preparation of carboxylic acid salts from primary alcohols | |
| WO2001019819A3 (en) | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |